Type2 Diabetes
305
11
19
201
Key Insights
Highlights
Success Rate
93% trial completion (above average)
Published Results
33 trials with published results (11%)
Research Maturity
201 completed trials (66% of total)
Clinical Risk Assessment
Based on trial outcomes
Moderate Risk
Score: 40/100
5.2%
16 terminated out of 305 trials
92.6%
+6.1% vs benchmark
15%
47 trials in Phase 3/4
16%
33 of 201 completed with results
Key Signals
Data Visualizations
Phase Distribution
Trial Status
Trial Success Rate
Benchmark: 86.5%
Based on 201 completed trials
Clinical Trials (305)
Comparative Effectiveness and Safety of Four Second Line Pharmacological Strategies in Type 2 Diabetes Study
Dietary Approaches to Stop Hypertension for Diabetes
Psychosocial, Environmental, and Chronic Disease Trends in Puerto Rico
The Effects of Evolocumab in Patients With Diabetes and Atherosclerotic Vascular Disease
Influence of Preprandial Metformin Administration on Carbohydrate Absorption
Cardio-metabolic and Inflammatory Impact of Starch Digestibility in Type 2 Diabetic Patients
Evaluate the Effects of Dapagliflozin in Patients With Type 2 Diabetes
Intensive Diet and Physical Activity on Diabetes
A Causative Role for Amylin in Diabetic Peripheral Neuropathy
Effects of Sitagliptin in Individuals With Genetically Decreased DPP4
The Mobile Lifestyle Intervention for Food and Exercise Study
Hypoglycemia and Autonomic Nervous System Function- B2
Brain Health in Youth With Normal Weight, Overweight and Obesity at Risk for Type 2 Diabetes (T2D)
UK Imaging Diabetes Study Seeing Diabetes Clearly
Metabolic Risk and Life Style Factors in Women With Previous Gestational Diabetes Mellitus (GDM)
OP5-005 Using Omnipod 5 in Adults With Type 2
A Study to Evaluate Tirzepatide (LY3298176) in Pediatric and Adolescent Participants With Type 2 Diabetes Mellitus Inadequately Controlled With Metformin or Basal Insulin or Both
Pemafibrate to Reduce Cardiovascular OutcoMes by Reducing Triglycerides IN patiENts With diabeTes (PROMINENT)
Depression & Insulin Sensitivity in Adolescents
Light, Metabolic Syndrome and Alzheimer's Disease - Aim 2